Sustained expression of human factor VIII in mice using a parvovirus- based vector

Blood

Volumn 95, Issue 5, 2000, Pages 1594-1599

  Chao, Hengjun ^a   Mao, Lan ^a   Bruce, Andrew T ^a   Walsh, Christopher E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMOPHILIA A; HISTOPATHOLOGY; LIVER CELL; MOUSE; NONHUMAN; PARVOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; TRANSGENE; VIRION;

EID: 0034161486     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1594.005k34_1594_1599     Document Type: Article

References (33)

1. Antonarakis S. Molecular genetics of coagulation factor VIII gene and haemophilia A. Haemophilia. 1998;4:1-11.
2. Lofqvist T, Nilsson I, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Int Med. 1997;241:395-400.
3. Liesner R. Prophylaxis in haemophilic children. Blood Coagul Fibrinolysis. 1997;8:S7-10.
4. Bohn R, Avorn J, Glynn R, Choodnovskiy I, Haschemeyer R, Aledort L. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost. 1998;79:932-937.
5. Aledort L, Bohn R. Prophylaxis and continuous infusion for hemophilia: can we afford it? Blood Coagul Fibrinolysis. 1996;7:935-937.
6. Dwarki V, Belloni P, Nijjar T, et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA. 1995;92:1023-1027.
7. Connelly S, Andrews J, Gallo A, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 1998;91:3273-3281.
8. Connelly S, Gardner J, Lyons R, McClelland A, Kaleko M. Sustained expression of therapeutic levels of human factor VIII in mice. Blood. 1996;87:4671-4677.
9. Connelly S, Mount J, Mauser A, et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood. 1996;88:3846-3853.
10. Rabinowitz J, Samulski J. Adeno-associated virus expression system for gene transfer. Curr Opin Biotechnol. 1998;9:470-475.
11. Snyder R, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5:64-70.
12. Wion K, Kelly D, Summertield J, Tuddenham E, Lawn R. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature. 1985;317:726-729.
13. Zelechowska M, van Mourik J, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature. 1985;317:729-730.
14. Dong J, Fan P, Frizzell R. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther. 1996;7:2101-2112.
15. Pittman D, Alderman E, Tomkinson K, Wang J, Giles A, Kaufman R. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII Blood. 1993;81:2925-2935.
16. Guo W, Bell K, Ou J. Characterization of the hepatitis B virus Enhl enhancer and X promoter complex. J Virol. 1991;65:6686-6692.
17. Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in Hemophilia B canines. Gene Ther. 1999;6:1695-1704.
18. Xiao X, Li J, Samulski R. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224-2232.
19. Ferrari F, Samulski T, Shenk T, Samulski R, Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996;70:3227-3234.
20. Kasper C, Aledort L, Aronson D, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorth. 1975;34:612.
21. Xiao W, Berta S, Lu M, Moscioni A, Tazelaar J, Wilson J. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol. 1998;72:10,222-10,226.
22. Herzog R, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56-63.
23. Fijnvandraat K, Berntorp E, ten Cate J. et al. Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients. Thromb Haemost. 1997;77:298-302.
24. Gnatenko D, Saenko E, Jesty J, Cao L, Hearing P, Bahou W. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. Br J Haematol. 1999;104:27-36.
25. Qian J, Borovok M, Bi L, Kazazian HJ, Hoyer L. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost. 1999;81:240-244.
26. Cai S-R, Kennedy S, Bowling W, Flye M, Ponder K. Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy. J Clin Invest. 1998;101:2831-2841.
27. Snyder R, Miao C, Patijn G, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270-276.
28. VandenDriessche T, Vanslembrouck V, Goovaerts I, et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII- deficient mice. Proc Natl Acad Sci USA. 1999;96:10,379-10,384.
29. Gilles J, Desqueper B, Lenk H, Vermylen J, Saint-Remy J. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest. 1996;97:1382-1388.
30. Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry. Thromb Haemost. 1994;72:155-158.
31. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost. 1992;67:600-602.
32. Miao C, Snyder R, Schowalter D, et al. The kinetics of rAAV integration in the liver. Nat Genet. 1998;19:13-15.
33. Fisher K, Gao G, Weitzman M, DeMatteo R, Burda J, Wilson J. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol. 1996;70:520-532.